Buscar
Congreso SOLACI

Búsqueda de: clopidogrel

Si no está conforme con los resultados, inténtelo de nuevamente.
Antiplatelet

Antiplatelet Treatment with Ticagrelor vs. Clopidogrel in Patients with Chronic Coronary Syndrome

Achieving rapid and maximum inhibition of platelet aggregation can reduce complications related to scheduled percutaneous coronary intervention...
solaci -
Ir
Acute coronary syndromes

Clopidogrel Monotherapy Beyond 12 months: Long Term Analysis of the STOPDAPT-2

Short dual antiplatelet therapy (DAPT) has shown benefits in patients receiving drug eluting stents (DES), reducing bleeding...
solaci -
Ir
Acute coronary syndromes

Substudy TALOS AMI: from Ticagrelor to Clopidogrel in Patients with High Risk of Bleeding and AMI

The preference for the use of potent P2Y12 inhibitors such as ticagrelor and prasugrel in patients with...
solaci -
Ir
Antiplatelet

ESC 2023 | Extended Monotherapy with Clopidogrel vs. DAPT in High-Risk Patients

An increasing number of patients currently present both an elevated ischemic risk and hemorrhagic risk. This means...
solaci -
Ir
Antithrombotic Anticoagulants

Is Clopidogrel Monotherapy Safe After a Month of Dual Antiplatelet Therapy in Diabetic Patients?

Currently, many randomized studies have suggested that short-term dual antiplatelet therapy (DAPT) followed by monotherapy reduces bleeding...
solaci -
Ir
Acute coronary syndromes

Abbreviated DAPT in ACS: The End of Clopidogrel Monotherapy?

Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to...
solaci -
Ir
Antiplatelet

Post TAVR Aspirin vs. Clopidogrel: Conflicting Findings and Guidelines

One month ago we shared a meta-analysis stating aspirin (ASA) as the best antiplatelet following TAVR vs....
solaci -
Ir
Antiplatelet

ACC 2021 | HOST-EXAM: Clopidogrel vs ASA monotherapy post DAPT in PCI patients

Clopidogrel monotherapy after dual antiplatelet therapy (DAPT) was associated with reduced mortality, MI, stroke, and other events...
solaci -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Selecting Renal Denervation Responsive Patients: Meta-Analysis of Observational Data

solaci - 0
Hypertension treatment has evolved considerably over time. However, managing adverse events driven by medication is still challenging, as is low patient adherence, be it...

Myocardial Damage in MAC

solaci - 0
Mitral annulus calcification (MAC) affects between 8% and 23% of the population. It is more common in women and patients with renal insufficiency. This...

Initial Complete Revascularization vs. Staged Revascularization in Patients with STEMI and Multivessel Disease

solaci - 0
In patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (primary PCI), multivessel disease is observed in up to 40%...

Noticias Institucionales

National and Internacional Live Cases at the Next SOLACI-CACI 2024

solaci - 0
Discover all the live national and international cases at the upcoming SOLACI-CACI 2024 Congress. Scientific program Register now con descuentos   Live International Transmission Tribute to Alain Cribier...

Discover the international guests of the SOLACI-CACI 2024 Congress

solaci - 0
We are getting closer to the largest gathering of interventional cardiologists in Latin America. Discover the prestigious guests from Europe, Asia, and the United...

New Issue of SOLACI-LATAM Peripheral Registry in the European Medical Journal

solaci - 0
We are proud to announce that the Latin American Society of Interventional Cardiology is sharing their latest issue of SOLACI-LATAM Peripheral Registry in the...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad